Dapsone-induced methemoglobinemia: A dose-related occurrence?

Cancer

Volumn 117, Issue 15, 2011, Pages 3485-3492

  Esbenshade, Adam J ^a   Ho, Richard H ^a   Shintani, Ayumi ^b   Zhao, Zhiguo ^b   Smith, Lesley Ann ^a   Friedman, Debra L ^a,c  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

cytochrome b5 reductase; dapsone; drug related complications; human immunodeficiency virus; methemoglobinemia; pediatric oncology

Indexed keywords

COTRIMOXAZOLE; CYTOCHROME B5 REDUCTASE; DAPSONE; HEMOGLOBIN; METHEMOGLOBIN; OXYGEN; PENTAMIDINE;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG ERUPTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOLYTIC ANEMIA; HIGH RISK PATIENT; HUMAN; HYPOXIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHEMOGLOBINEMIA; NAUSEA; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTOPENIA;

ANEMIA, APLASTIC; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DAPSONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; METHEMOGLOBINEMIA; MULTIVARIATE ANALYSIS; PNEUMONIA, PNEUMOCYSTIS; PROPORTIONAL HAZARDS MODELS;

EID: 79960698482     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25904     Document Type: Article

References (31)

1. Hughes WT,. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis. 1998; 27: 191-204. (Pubitemid 28334441)
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730-751. (Pubitemid 34194843)
3. Ash-Bernal R, Wise R, Wright SM,. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004; 83: 265-273. (Pubitemid 39258412)
4. Williams S, MacDonald P, Hoyer JD, Barr RD, Athale UH,. Methemoglobinemia in children with acute lymphoblastic leukemia (ALL) receiving dapsone for Pneumocystis carinii pneumonia (PCP) prophylaxis: a correlation with cytochrome b5 reductase (Cb5R) enzyme levels. Pediatr Blood Cancer. 2005; 44: 55-62. (Pubitemid 39602568)
5. Zosel A, Rychter K, Leikin JB,. Dapsone-induced methemoglobinemia: case report and literature review. Am J Ther. 2007; 14: 585-587. (Pubitemid 350307696)
6. Blum RN, Miller LA, Gaggini LC, Cohn DL,. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992; 5: 341-347.
7. Kemper CA, Tucker RM, Lang OS, et al. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS. 1990; 4: 1145-1148.
8. Coleman MD, Jacobus DP,. Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. Biochem Pharmacol. 1993; 45: 1027-1033. (Pubitemid 23079979)
9. Efron B, Tibshirani R,. An introduction to the bootstrap. New York, NY: Chapman & Hall; 1993.
10. Harrell FE,. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York, NY: Springer; 2001.
11. Dupont WD, Plummer WD Jr. , Power and sample size calculations. A review and computer program. Control Clin Trials. 1990; 11: 116-128. (Pubitemid 20136185)
12. Dunford LM, Roy DM, Hahn TE, et al. Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006; 12: 241-242. (Pubitemid 43138019)
13. Hamirani YS, Franklin W, Grifka RG, Stainback RF,. Methemoglobinemia in a young man. Tex Heart Inst J. 2008; 35: 76-77. (Pubitemid 351581314)
14. Ward KE, McCarthy MW,. Dapsone-induced methemoglobinemia. Ann Pharmacother. 1998; 32: 549-553. (Pubitemid 28232760)
15. Mandrell BN, McCormick JN,. Dapsone-induced methemoglobinemia in pediatric oncology patients: case examples. J Pediatr Oncol Nurs. 2001; 18: 224-228. (Pubitemid 33602020)
16. Manfredi G, De Panfilis G, Zampetti M, Allegra F,. Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage. Br J Dermatol. 1979; 100: 427-432. (Pubitemid 9251081)
17. Cruciani M, Gatti G, Mengoli C, et al. Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 1997; 41: 1077-1081. (Pubitemid 27194189)
18. Gatti G, Merighi M, Hossein J, et al. Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1996; 40: 2743-2748. (Pubitemid 26404336)
19. Gatti G, Fioredda F, Lorusso C, Cruciani M, Bassetti D,. Alternative dapsone dosage regimen for prophylaxis of Pneumocystis carinii pneumonia. Pediatr Infect Dis J. 1996; 15: 183-184. (Pubitemid 26066510)
20. Gatti G, Loy A, Casazza R, Miletich F, Cruciani M, Bassetti D,. Pharmacokinetics of dapsone in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 1995; 39: 1101-1106.
21. Gatti G, Loy A, Lorusso C, Rossi G, Bassetti D,. Penetration of dapsone into lung of human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1997; 16: 523-524. (Pubitemid 27212792)
22. McIntosh K, Cooper E, Xu J, et al. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team AIDS Clinical Trials Group. Pediatr Infect Dis J. 1999; 18: 432-439. (Pubitemid 29247012)
23. Fermo E, Bianchi P, Vercellati C, et al. Recessive hereditary methemoglobinemia: 2 novel mutations in the NADH-cytochrome b5 reductase gene. Blood Cells Mol Dis. 2008; 41: 50-55.
24. Schuurman M, van Waardenburg D, Da Costa J, Niemarkt H, Leroy P,. Severe hemolysis and methemoglobinemia following fava beans ingestion in glucose-6-phosphatase dehydrogenase deficiency: case report and literature review. Eur J Pediatr. 2009; 168: 779-782.
25. Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH,. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant. 2000; 6: 35-43.
26. Kim SY, Dabb AA, Glenn DJ, Snyder KM, Chuk MK, Loeb DM,. Intravenous pentamidine is effective as second line pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer. 2008; 50: 779-783. (Pubitemid 351354784)
27. Gupta M, Stephenson K, Gauar S, Frenkel L,. Intravenous pentamidine as an alternate for Pneumocystis carinii pneumonia prophylaxis in children with HIV infection. Pediatr Pulmonol Suppl. 1997; 16: 199-200. (Pubitemid 28070823)
28. Milstone AM, Balakrishnan SL, Foster CB, Chen A,. Failure of intravenous pentamidine prophylaxis to prevent pneumocystis pneumonia in a pediatric hematopoietic stem cell transplant (HSCT) patient. Pediatr Blood Cancer. 2006; 47: 859-860. (Pubitemid 44476770)
29. Thomas SH, Page CJ, Blower PJ, et al. Disposition of intravenous 123iodopentamidine in man. Nucl Med Biol. 1997; 24: 327-332.
30. Prasad P, Nania JJ, Shankar SM,. Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer. 2008; 50: 896-898. (Pubitemid 351354814)
31. Madden RM, Pui CH, Hughes WT, Flynn PM, Leung W,. Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer. 2007; 109: 1654-1658. (Pubitemid 46595702)